TipRanks
Advertisement
Advertisement
BridgeBio Wins FDA Priority Review for Infigratinib
PremiumCompany AnnouncementsBridgeBio Wins FDA Priority Review for Infigratinib
8d ago
BridgeBio announces real-world evidence, Phase 3 ATTRibute CM sub-analyses
Premium
The Fly
BridgeBio announces real-world evidence, Phase 3 ATTRibute CM sub-analyses
10d ago
BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret
Premium
The Fly
BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret
10d ago
BridgeBio Pharma: Buy Rating Reiterated on Strong FORTIFY Phase 3 Data; 12-Month $120 Price Target Maintained
PremiumRatingsBridgeBio Pharma: Buy Rating Reiterated on Strong FORTIFY Phase 3 Data; 12-Month $120 Price Target Maintained
15d ago
BridgeBio Pharma presents new data from interim analysis of FORTIFY study
Premium
The Fly
BridgeBio Pharma presents new data from interim analysis of FORTIFY study
16d ago
Mizuho biotech analysts hold an analyst/industry conference call
Premium
The Fly
Mizuho biotech analysts hold an analyst/industry conference call
20d ago
BridgeBio Pharma price target raised to $110 from $96 at Mizuho
PremiumThe FlyBridgeBio Pharma price target raised to $110 from $96 at Mizuho
2M ago
BridgeBio Pharma Expands Access to Rare Disease Therapies
Premium
Company Announcements
BridgeBio Pharma Expands Access to Rare Disease Therapies
2M ago
BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study
Premium
The Fly
BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―